Biomoda Expands IP Portfolio with Canadian Patent, Trademark Protection in EU

Biomoda (OTCBB: BMOD) has announced significant additions to its Intellectual Property (IP) portfolio, including a Canadian patent for using its proprietary porphyrin-based compound to detect cancer and trademark protection for Biomoda’s CyPath® assay kits and reagents in the European Union.

According to John Cousins, President of Biomoda, “While we work toward FDA approval and commercialization of our CyPath® diagnostic for lung cancer, it is critically important to make sure that our technology and the IP behind it are protected.  Cancer is a global health crisis with the number of diagnoses and deaths expected to double by 2030. We will continue to expand the geographic reach of our IP protection in order to make the CyPath® assay available worldwide.”

Read More

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: